Breaking News Instant updates and real-time market news.

TRVN

Trevena

$0.63

-0.0207 (-3.18%)

07:21
12/10/18
12/10
07:21
12/10/18
07:21

Trevena appoints Robert Yoder to CBO

Trevena announced the promotion of Robert Yoder from VP commercial operations and sales to the newly created position of senior VP and CBO, effective immediately. Yoder brings to this position over 30 years of industry experience across a wide range of functions and therapeutic areas, including acute care. Yoder joined Trevena as VP of commercial operations and sales in June. Prior to this, he served as senior VP and head of global commercial operations, alliance management and IT at Orexigen Therapeutics, a biopharmaceutical company, from March 2015 through June. While at Orexigen, Yoder built the commercial infrastructure. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries.

TRVN Trevena
$0.63

-0.0207 (-3.18%)

11/05/18
HCWC
11/05/18
DOWNGRADE
Target $0.75
HCWC
Neutral
Trevena downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Trevena to Neutral and lowered his price target for the shares to 75c from $3.00. Following the Complete Response Letter from the FDA on the new drug application for oliceridin, a second-pass PDUFA date is unlikely until early 2020, Arce tells investors in a research note. He believes the CRL "leaves several open questions."
10/12/18
HCWC
10/12/18
NO CHANGE
Target $3
HCWC
Buy
H.C. Wainwright says FDA nod for Trevena's oliceridine unlikely, but possible
H.C. Wainwright analyst Ed Arce said he does not believe the FDA's approval decision about Trevena's oliceridine is "a foregone conclusion" following yesterday's advisory committee meeting given the mixed vote on approvability. After the vote, at least three panelists who voted "no" said that they struggled with their decision and could have easily voted "yes," according to Arce, who said there is a possibility, "however unlikely," that the FDA could still approve the drug. While he views the November 2 decision as "too hard to call" and keeps a Buy rating on Trevena shares, Arce lowered his price target on the stock to $3 from $7.
10/12/18
JMPS
10/12/18
NO CHANGE
Target $4
JMPS
Outperform
Trevena price target lowered to $4 from $15 at JMP Securities
JMP Securities analyst Jason Butler said the mixed Advisory Committee vote on Trevena's application for oliceridine is likely to result in an approval delay, but he has not given up on the potential for issues raised by the panel to be addressed with label modifications and post-marketing studies. He now assume the company receiving a CRL as his base case scenario, which would result in an 18-month delay to approval. Butler, who cut his probability of approval for oliceridine to 70% from 90% and lowered his peak sales estimate, reduced his price target on Trevena shares to $4 from $15 but keeps an Outperform rating on the stock.
10/12/18
NEED
10/12/18
DOWNGRADE
NEED
Hold
Trevena downgraded to Hold at Needham on oliceridine recommendation
As reported earlier, Needham analyst Alan Carr downgraded Trevena to Hold after the FDA's Administration Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, voted 7-8 against the approval of oliceridine use in acute pain management. The analyst notes that documents from the FDA released this week also showed some reluctance in the drug's overall profile, and combined with this latest AADPAC decision, render the approval of oliceridine as improbable. Carr adds that Trevena will likely face challenges obtaining financial resources to support commercial launch even if oliceridine was approved next month, noting that he now awaits the official FDA decision and discussion of development for Trevena's other pipeline programs.

TODAY'S FREE FLY STORIES

APRE

Aprea Therapeutics

$26.92

2.45 (10.01%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Earnings
Aprea Therapeutics reports Q3 EPS ($5.29), consensus ($3.94) »

As of September 30, prior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$209.88

1.33 (0.64%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Earnings
Nvidia reports Q3 adjusted EPS $1.78, consensus $1.57 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/14/19
11/14
16:20
11/14/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 14th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$175.21

2 (1.15%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Hot Stocks
Breaking Hot Stocks news story on RH »

RH up 7% in afterhours…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Earnings
Dolby sees FY20 adjusted EPS $3.40-$3.50, consensus $2.87 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

CSSE

Chicken Soup for the Soul

$9.99

0.28 (2.88%)

16:19
11/14/19
11/14
16:19
11/14/19
16:19
Earnings
Chicken Soup for the Soul reports Q3 adjusted EPS ($1.03), consensus (5c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Earnings
Dolby sees Q1 adjusted EPS 45c-51c, consensus 65c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

CY

Cypress Semiconductor

$23.43

0.01 (0.04%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Downgrade
Cypress Semiconductor rating change  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$91.26

-0.02 (-0.02%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Hot Stocks
Nike raises quarterly dividend to 24.5c from 22c per share »

The dividend declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$109.21

4.195 (3.99%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Earnings
Globant raises FY19 non-IFRS EPS view to $2.23-$2.27 from $2.19-$2.25 »

Consensus $2.24. Narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/14/19
11/14
16:17
11/14/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$1.38

0.29 (26.73%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Celsion reports Q3 EPS (25c), consensus (28c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

HAYN

Haynes

$35.83

-0.31 (-0.86%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Haynes reports Q4 EPS 48c, consensus 40c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

DLB

Dolby

$65.56

-0.14 (-0.21%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Dolby reports Q4 adjusted EPS 66c, consensus 48c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

GLOB

Globant

$109.21

4.195 (3.99%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Globant sees Q4 non-IFRS adjusted EPS 58c-62c, consensus 63c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GIFI

Gulf Island Fabrication

$4.38

0.07 (1.62%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Hot Stocks
Gulf Island Fabrication board Chairman Jack Laborde to step down »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$109.21

4.195 (3.99%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Earnings
Globant reports Q3 non-IFRS EPS 62c, consensus 59c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/14/19
11/14
16:16
11/14/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$175.21

2 (1.15%)

, BRK.A

Berkshire Hathaway

$329,095.00

-505 (-0.15%)

16:15
11/14/19
11/14
16:15
11/14/19
16:15
Hot Stocks
Warren Buffet's Berkshire Hathaway takes stake in RH »

The stake in RH was…

RH

RH

$175.21

2 (1.15%)

BRK.A

Berkshire Hathaway

$329,095.00

-505 (-0.15%)

BRK.B

Berkshire Hathaway

$219.42

-0.39 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/14/19
11/14
16:15
11/14/19
16:15
General news
Breaking General news story  »

Week of 11/4 Money Supply…

16:15
11/14/19
11/14
16:15
11/14/19
16:15
General news
Breaking General news story  »

Week of 11/13 Fed Balance…

HPQ

HP Inc.

$20.12

0.585 (2.99%)

, CLDR

Cloudera

$8.54

0.055 (0.65%)

16:14
11/14/19
11/14
16:14
11/14/19
16:14
Hot Stocks
Icahn bought 62.9M shares of HP, 54.8M shares of Cloudera in Q3 »

Carl Icahn disclosed in a…

HPQ

HP Inc.

$20.12

0.585 (2.99%)

CLDR

Cloudera

$8.54

0.055 (0.65%)

HTZ

Hertz

$16.27

-0.03 (-0.18%)

CZR

Caesars

$12.86

0.09 (0.70%)

CNDT

Conduent

$6.57

-0.07 (-1.06%)

IEP

Icahn Enterprises

$64.94

-0.1 (-0.15%)

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

LNG

Cheniere Energy

$61.18

-0.1 (-0.16%)

FCX

Freeport McMoRan

$10.81

-0.02 (-0.18%)

CVI

CVR Energy

$46.82

0.32 (0.69%)

HLF

Herbalife Nutrition

$43.57

-0.23 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

ZSAN

Zosano Pharma

$1.98

-0.04 (-1.98%)

16:13
11/14/19
11/14
16:13
11/14/19
16:13
Earnings
Zosano Pharma reports Q3 EPS (55c), consensus (58c) »

As of September 30, cash,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SNNA

Sienna Biopharmaceuticals

$0.27

0.1092 (67.91%)

16:13
11/14/19
11/14
16:13
11/14/19
16:13
Hot Stocks
Sienna announces court approval of Chapter 11 bidding procedures »

Sienna Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCX

OncoCyte

$1.62

-0.01 (-0.61%)

16:12
11/14/19
11/14
16:12
11/14/19
16:12
Earnings
OncoCyte reports Q3 EPS (10c), consensus (9c) »

At September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.